Kezar Life Sciences - KZR STOCK NEWS

Kezar Life Sciences (Nasdaq: KZR) announced its participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing from November 18 at 3:00 a.m. EST. The webcast can be accessed through the Events & Presentations section on Kezar's website, with an archived replay available for 90 days post-conference. The company focuses on developing treatments for immune-mediated and oncologic disorders, with KZR-616 in Phase 2 trials and KZR-261 in Phase 1 trials.

Kezar Life Sciences has closed a $50 million senior secured term loan with Oxford Finance LLC. The funds will be utilized for general growth capital and to advance clinical candidates KZR-616 and KZR-261. The financing aims to strengthen Kezar's balance sheet and support the ongoing development of its innovative therapies targeting immune-mediated and oncologic disorders. The company anticipates top-line data readouts for KZR-616 in Q2 2022, enhancing its prospects in the competitive biopharmaceutical landscape.

Kezar Life Sciences (KZR) announced significant clinical progress in its drug development pipeline. The company achieved target enrollment in the MISSION Phase 2 trial for KZR-616 in lupus nephritis and initiated dosing for KZR-261 in a Phase 1 trial for advanced solid tumors. A new credit facility provides up to $50 million in funding. Financially, Kezar reported a net loss of $14.5 million for Q3 2021, up from $11.3 million year-over-year. Cash and equivalents stood at $120.8 million, down from $140.4 million at year-end 2020.

Kezar Life Sciences, Inc. (Nasdaq: KZR) will host a virtual Investor and Analyst Day on November 15, 2021, at 4:30 p.m. ET. The event will highlight interim data from the MISSION study on KZR-616, a selective immunoproteasome inhibitor for lupus nephritis. Additionally, KZR-261, a novel anti-tumor agent, will be discussed, alongside the Phase 1 trial design. Presenters include CEO John Fowler and CMO Noreen Roth Henig. The presentation will be followed by a Q&A session. Register at event link.

Kezar Life Sciences (NASDAQ: KZR) announced the dosing of the first patient in the KZR-261-101 trial, evaluating KZR-261, a novel anti-tumor agent. This Phase 1 study aims to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with solid tumors. The trial consists of a dose escalation and expansion phase. KZR-261 is the first clinical candidate from Kezar's protein secretion platform, targeting the Sec61 translocon. The company anticipates that KZR-261's unique profile may offer significant potential in oncology.

Kezar Life Sciences (NASDAQ: KZR) has appointed Gitanjali Jain as Vice President of Investor Relations and External Affairs. Jain brings over 15 years of healthcare experience, previously advising biopharmaceutical companies at Solebury Trout. She will guide Kezar's investor relations and scientific communications. CEO John Fowler expressed enthusiasm about her addition, anticipating her expertise will enhance the company's efforts in developing therapies for immune-mediated and oncologic disorders, including KZR-616 and KZR-261.

Kezar Life Sciences (Nasdaq: KZR) has announced participation in two upcoming virtual investor conferences. The Wells Fargo Virtual Healthcare Conference is scheduled for September 9, 2021, at 4:00 PM ET, featuring CEO John Fowler and CMO Noreen Roth Henig. The H. C. Wainwright 23rd Annual Global Investment Conference will occur on September 13, 2021, at 7:00 AM ET, with John Fowler presenting. Webcasts can be accessed on the company’s website and will be archived for 90 days.

Kezar Life Sciences, Inc. (KZR) has completed enrollment in its Phase 2 PRESIDIO trial, evaluating KZR-616 for polymyositis (PM) and dermatomyositis (DM). The study, which involves 24 subjects, is a randomized, placebo-controlled trial designed to assess safety and efficacy over 32 weeks. Patients receive either KZR-616 or placebo, with top-line results expected in Q2 2022. KZR-616 has received Orphan Drug Designation from the FDA for PM and DM. This milestone is viewed as significant for advancing treatment options for these debilitating conditions.

Kezar Life Sciences, Inc. (KZR) reported its second quarter 2021 financial results, highlighting the completion of a Phase 1b study for KZR-616, which showed positive safety and efficacy in lupus nephritis patients. The company submitted an IND for KZR-261, aiming to initiate a Phase 1 trial for this anti-tumor agent. Q2 2021 net loss was $13 million, or $0.25 per share, compared to a loss of $9.5 million, or $0.22 per share, in Q2 2020. Cash reserves decreased from $140 million at year-end 2020 to $129 million, attributed to R&D expenses.